Trial watch: Toll-like receptor ligands in cancer therapy-Reference-Cited by-同舟云学术

Trial watch: Toll-like receptor ligands in cancer therapy

Published:2023-02-17 Issue:1 Volume:12 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Le Naour Julie¹²^ORCID,Kroemer Guido¹³

Affiliation:

1. Centre de Recherche Des Cordeliers, Equipe Labellisée Par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France

2. Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France

3. Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France

Funder

that there is no funding associated with the work featured in this article

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2023.2180237

Reference67 articles.

1. Toll-like receptors — taking an evolutionary approach

2. The evolution of vertebrate Toll-like receptors

3. Toll-Like Receptor Signaling Pathways

4. Toll-like receptors and innate immunity

5. Intracellular Toll-like Receptors

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual and multi-immune activation strategies for emerging cancer immunotherapy;Materials Today;2024-09

2. Comparative network-based analysis of toll-like receptor agonist, L-pampo signaling pathways in immune and cancer cells;Scientific Reports;2024-07-26

3. High‐risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects;Journal of Medical Virology;2024-05-24

4. Human and Murine Toll-like Receptor-Driven Disease in Systemic Lupus Erythematosus;International Journal of Molecular Sciences;2024-05-14

5. Toll‐like receptors in health and disease;MedComm;2024-04-29